Is the Ozempic Lawsuit Real? Who May Qualify

If you or someone you love took Ozempic and later lost vision, you have probably seen ads asking whether you qualify for a lawsuit — and you may be wondering whether any of it is legitimate. The short answer is yes: there is real litigation moving through the federal court system. The longer answer, and the one that actually matters for you, is more careful. Whether you have a claim is not something a commercial can decide. It is something an experienced Ozempic lawsuit attorney evaluates based on your specific facts.

This article explains what the litigation actually is, what injury it centers on, and the factors a lawyer looks at when reviewing a potential case. It is general legal information, not legal advice or a promise about your situation. Because this litigation is moving quickly, we mark the time-sensitive details so you know to confirm them before you rely on them.

So, is the Ozempic lawsuit real?

Yes. As of June 2026, there is active, coordinated litigation in U.S. federal court. In December 2025, the U.S. Judicial Panel on Multidistrict Litigation created a multidistrict litigation, MDL No. 3163 (In re: GLP-1 RAs (NAION) Products Liability Litigation), in the U.S. District Court for the Eastern District of Pennsylvania before Judge Karen Spencer Marston. It centralizes lawsuits alleging that GLP-1 receptor agonist drugs — a class that includes Ozempic, as well as related semaglutide and tirzepatide medications — are linked to a serious eye condition. The cases were assigned to a single federal judge to handle pretrial proceedings in a coordinated way. (Source: U.S. Judicial Panel on Multidistrict Litigation, jpml.uscourts.gov.)

A multidistrict litigation is not the same thing as a class action. In an MDL, each person keeps their own individual case; the cases are simply grouped together for efficiency so that shared questions — like the science and the company's knowledge — can be worked through once instead of thousands of times. If that distinction matters to you, we explain it in plain English in our guide to mass tort vs. class action.

What injury is the Ozempic lawsuit about?

The vision-loss cases center on a condition called NAION — non-arteritic anterior ischemic optic neuropathy. NAION happens when blood flow to the optic nerve is reduced, damaging the nerve and often causing sudden, painless, and frequently permanent vision loss, usually in one eye. People often describe waking up with a dark area, a blind spot, or sharply reduced vision that does not come back.

The legal claims trace back in part to medical research. A 2025 study published in JAMA Ophthalmology reported that patients prescribed semaglutide — the active ingredient in Ozempic — experienced NAION at a higher rate than comparable patients on other medications. Lawsuits generally allege that the manufacturer knew or should have known about the potential risk and failed to adequately warn patients and doctors. Importantly, a study showing an association is not the same as a court finding the drug legally caused a specific person's injury; that is exactly what this litigation is working to determine.

Ozempic has also been discussed in connection with other reported injuries, such as severe gastrointestinal problems, which are part of a separate and larger federal litigation. This article focuses on the vision-loss (NAION) claims. If you experienced a different injury, an attorney can still review which litigation, if any, fits your situation.

Who may qualify? The factors an attorney evaluates

Here is the part the ads tend to skip. "Qualifying" is not a yes-or-no box you check on a website — it is a legal evaluation. When reviewing a potential Ozempic claim, an attorney generally looks at factors like these:

• The medication. Which specific GLP-1 drug you took (Ozempic or a related medication), and ideally documentation such as prescriptions or pharmacy records.
• Duration and timing. How long you used the medication and when, relative to when your symptoms appeared.
• The diagnosis. A medical diagnosis of NAION or similar optic-nerve injury, supported by records from your eye doctor or treating physician.
• Medical history. Other health factors that could be relevant, which the attorney and medical experts weigh as part of the full picture.
• Deadlines. Your state's statute of limitations — the legal deadline to file — which can be shorter than people expect.

Meeting these factors may mean your case is worth a closer look. It does not guarantee compensation, and any attorney who tells you otherwise before reviewing your records is not being straight with you. The purpose of a case review is to find out, honestly, whether you have a claim worth pursuing. You can learn more about how these claims work on our page about dangerous drug lawsuits.

What about settlement amounts?

We understand this is often the first question, so we will be direct: there are no settlement amounts to report. The NAION litigation is in an early stage. There has been no global settlement and no jury verdict that establishes what these cases are worth. Any specific dollar figure you see in an advertisement is speculation, not a promise that applies to you.

Prior results in other cases do not guarantee a similar outcome, and the value of any individual claim — if it has value at all — depends on facts that have not yet been decided in this litigation. Treat confident-sounding numbers with healthy skepticism.

Why timing matters

Two clocks are running at the same time. The first is your state's statute of limitations, the legal deadline to bring a claim. Miss it, and even a strong case can be barred forever. These deadlines vary by state and can be affected by when an injury was discovered, which is one reason waiting is risky.

The second is practical: medical records, pharmacy histories, and your own memory of dates are easier to gather sooner rather than later. Acting promptly gives an attorney the best chance to evaluate your case while the evidence is still accessible. If you are unsure whether your timeline still works, that itself is a good reason to ask.

How De La Rosa Law can help

De La Rosa Law helps people who believe they were harmed by a dangerous or defective drug understand their options and, where appropriate, pursue a claim. Pharmaceutical injury cases like the GLP-1 NAION litigation are complex and document-heavy, and they are often handled together with co-counsel who focus on this type of mass-tort work. We will explain who would be working on your matter, and how, before you sign anything.

You can review the kinds of claims we handle on our mass tort page. And because clear communication should never be a barrier, our team works in both English and Spanish — Se Habla Español.

A case review costs you nothing and does not obligate you to anything. If you took Ozempic or another GLP-1 medication and later experienced vision loss, the most useful next step is simply to ask a lawyer to look at your facts. Use the form below to request a free, confidential evaluation.